Article
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Nature communications - 26 Mar 2021
Kottke Timothy, Tonne Jason, Evgin Laura, Driscoll Christopher B, van Vloten Jacob, Jennings Victoria A, Huff Amanda L, Zell Brady, Thompson Jill M, Wongthida Phonphimon, Pulido Jose, Schuelke Matthew R, Samson Adel, Selby Peter, Ilett Elizabeth, McNiven Mark, Roberts Lewis R, Borad Mitesh J, Pandha Hardev, Harrington Kevin, Melcher Alan, Vile Richard G
Abstract excerpt
In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-mutated CSDE1P5S form of the RNA-binding Cold Shock Domain-containing E1 protein, which promotes escape as an inhibitor of VSV replication by disrupting viral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.